While there are yet no studies determining the oncogenic drive of simultaneous mutations in BRCA1/2 and HER2, there are likely tumours that either show combined BRCA1/2 and HER2 mutation, or HER2 amplification with an intact BRCA1/2 pathway. This evidence concerns the gene BRCA1 and neoplasm.